Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1950 1
1951 1
1952 2
1953 2
1954 1
1956 1
1961 1
1962 4
1963 1
1964 1
1966 1
1967 3
1968 9
1969 17
1970 22
1971 24
1972 18
1973 18
1974 16
1975 13
1976 10
1977 11
1978 25
1979 23
1980 33
1981 21
1982 25
1983 41
1984 39
1985 41
1986 44
1987 68
1988 54
1989 48
1990 63
1991 53
1992 69
1993 60
1994 51
1995 44
1996 55
1997 57
1998 47
1999 64
2000 86
2001 114
2002 126
2003 158
2004 168
2005 196
2006 246
2007 273
2008 293
2009 283
2010 331
2011 262
2012 221
2013 218
2014 225
2015 286
2016 273
2017 277
2018 331
2019 340
2020 332
2021 303
2022 169
2023 80
2024 64

Text availability

Article attribute

Article type

Publication date

Search Results

6,266 results

Results by year

Filters applied: . Clear all
Page 1
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V. Wen PY, et al. Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.
Relugolix.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Apr 22;78(9):762-763. doi: 10.1093/ajhp/zxab036. Am J Health Syst Pharm. 2021. PMID: 33704417 No abstract available.
Vibegron.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Apr 22;78(9):764-765. doi: 10.1093/ajhp/zxab037. Am J Health Syst Pharm. 2021. PMID: 33704365 No abstract available.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Gershenson DM, et al. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. Lancet. 2022. PMID: 35123694 Free PMC article. Clinical Trial.
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB. Tian J, et al. Nat Med. 2023 Feb;29(2):458-466. doi: 10.1038/s41591-022-02181-8. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702949 Free PMC article. Clinical Trial.
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA. Al-Hendy A, et al. Obstet Gynecol. 2022 Dec 1;140(6):920-930. doi: 10.1097/AOG.0000000000004988. Epub 2022 Nov 2. Obstet Gynecol. 2022. PMID: 36357960 Free PMC article. Clinical Trial.
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
Grenier A, Poulain L, Mondesir J, Jacquel A, Bosc C, Stuani L, Mouche S, Larrue C, Sahal A, Birsen R, Ghesquier V, Decroocq J, Mazed F, Lambert M, Andrianteranagna M, Viollet B, Auberger P, Lane AA, Sujobert P, Bouscary D, Sarry JE, Tamburini J. Grenier A, et al. Cell Rep. 2022 Jan 4;38(1):110197. doi: 10.1016/j.celrep.2021.110197. Cell Rep. 2022. PMID: 34986346 Free article.
6,266 results